Literature DB >> 16174493

Management of co-morbidities and general medical conditions in patients with rheumatoid arthritis.

Molly D Magnano1, Mark C Genovese.   

Abstract

Rheumatologists, in addition to providing subspecialty care, are frequently called to treat general medical conditions in their patients with rheumatoid arthritis (RA). Co-morbid medical problems are common in the RA population and may require a different approach from standard practice recommendations. In this paper, we review the evaluation and treatment of cardiovascular disease, chronic kidney disease, gastrointestinal disease, depression, and metabolic bone disease in patients with RA. Appreciation of the unique interaction between arthritis and common medical co-morbidities may have a significant impact on management and outcomes of RA.

Entities:  

Mesh：

Year:  2005        PMID： 16174493     DOI： 10.1007/s11926-005-0030-y

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


  70 in total

Review 1.  Adverse renal effects of anti-inflammatory agents: evaluation of selective and nonselective cyclooxygenase inhibitors.

Authors:  G Gambaro; M A Perazella
Journal:  J Intern Med       Date:  2003-06       Impact factor: 8.989

Review 2.  Epidemiology of rheumatoid arthritis: update.

Authors:  M C Hochberg; T D Spector
Journal:  Epidemiol Rev       Date:  1990       Impact factor: 6.222

3.  Long-term nonsteroidal anti-inflammatory drug use and gastroduodenal injury: the role of Helicobacter pylori.

Authors:  D S Loeb; N J Talley; D A Ahlquist; H A Carpenter; A R Zinsmeister
Journal:  Gastroenterology       Date:  1992-06       Impact factor: 22.682

4.  Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs.

Authors:  L A García Rodríguez; H Jick
Journal:  Lancet       Date:  1994-03-26       Impact factor: 79.321

5.  Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women.

Authors:  S L Greenspan; H N Rosen; R A Parker
Journal:  J Clin Endocrinol Metab       Date:  2000-10       Impact factor: 5.958

6.  High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors.

Authors:  I D del Rincón; K Williams; M P Stern; G L Freeman; A Escalante
Journal:  Arthritis Rheum       Date:  2001-12

Review 7.  Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications--review and recommendations based on risk assessment.

Authors:  F K L Chan; D Y Graham
Journal:  Aliment Pharmacol Ther       Date:  2004-05-15       Impact factor: 8.171

Review 8.  [Kidney involvement in rheumatoid arthritis].

Authors:  A Icardi; P Araghi; M Ciabattoni; U Romano; P Lazzarini; G Bianchi
Journal:  Reumatismo       Date:  2003

Review 9.  Principles of rheumatoid arthritis control.

Authors:  Tom G Palferman
Journal:  J Rheumatol Suppl       Date:  2003-08

10.  Evaluation of calcaneal quantitative ultrasound in a primary care setting as a screening tool for osteoporosis in postmenopausal women.

Authors:  Adolfo Díez-Pérez; Fernando Marín; Joan Vila; Mercedes Abizanda; Artur Cervera; Cristina Carbonell; Rosa Ma Alcolea; Adoración Cama; Teresa Rama; Elena Galindo; Carmen Olmos
Journal:  J Clin Densitom       Date:  2003       Impact factor: 2.963
View more
  3 in total

1.  Comparison of comorbidities of the Egyptian rheumatoid arthritis patients to the global cohort of the COMORA study: a post-hoc analysis.

Authors:  Bassel El-Zorkany; Abir Mokbel; Sherif M Gamal; Maha Mousa; Mohamed Youssef; Ihsane Hmamouchi
Journal:  Clin Rheumatol       Date:  2015-12-15       Impact factor: 2.980

2.  Effect of anti-tumor necrosis factor alpha treatment of rheumatoid arthritis and chronic kidney disease.

Authors:  Hyun Woo Kim; Chang-Keun Lee; Hoon-Suk Cha; Jung-Yoon Choe; Eun-Jung Park; Jinseok Kim
Journal:  Rheumatol Int       Date:  2014-10-08       Impact factor: 2.631

3.  Clinical efficacy, radiographic progression, and safety through 156 weeks of therapy with subcutaneous golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis despite prior methotrexate therapy: final results of the randomized GO-FORTH trial.

Authors:  Yoshiya Tanaka; Masayoshi Harigai; Tsutomu Takeuchi; Hisashi Yamanaka; Naoki Ishiguro; Kazuhiko Yamamoto; Nobuyuki Miyasaka; Takao Koike; Daniel Baker; Yutaka Ishii; Toru Yoshinari
Journal:  Mod Rheumatol       Date:  2015-12-23       Impact factor: 3.023
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.